Background Despite advances in targeted therapies, there is an ongoing need to develop
new and effective cytotoxic drug combinations in non-small cell lung cancer (NSCLC) …

Pemetrexed is an antitumor agent traditionally used as monotherapy for the second-line
treatment of patients with locally advanced or metastatic non-small cell lung cancer …

Lung cancer is the leading cause of cancer-related mortality. This study was undertaken to
investigate the efficacy and safety of adding regulatory T cell inhibitor cyclophosphamide to …

Background and objective Platinum-based doublet chemotherapy is still the standard first-
line treatment for non-small cell lung cancer (NSCLC). Previous studies have demonstrated …

8050 Background: The role of platinum compounds as part of second line therapies in
advanced NSCLC is ill defined. We performed a randomized phase II trial comparing P and …

PURPOSE To compare the efficacy and toxicity of pemetrexed versus docetaxel in patients
with advanced non-small-cell lung cancer (NSCLC) previously treated with chemotherapy …

INTRODUCTION: Treatment with epidermal growth factor receptor (EGFR)-tyrosine kinase
inhibitors or chemotherapy have shown improved survival outcomes in East Asian, never …

Background: Before the approval of first-line immune checkpoint inhibitors, platinum
doublets were the standard of care in patients with treatment-naïve advanced non-small cell …

Background: Although pemetrexed/cisplatin (PC) is a standard treatment for advanced non-
squamous non-small cell lung cancer (Nsq-NSCLC), neither its efficacy nor the effects of …

Purpose Pemetrexed is a recognized active agent for the second-line treatment for
advanced non-small cell lung cancer (NSCLC). This study was undertaken to evaluate the …